Compare Chubb Ltd (CB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Chubb Ltd trades at $345.98 (market cap $134.28B), while Zimmer Biomet Holdings Inc trades at $90.42 (market cap $17.61B). The key difference: Chubb Ltd is far larger — about 7.6× Zimmer Biomet Holdings Inc's market cap, and Chubb Ltd pays the higher dividend (1.18%). Which is the better fit depends on your goals.
| CB | ZBH | |
|---|---|---|
Market Cap | $134.28B | $17.61B |
Sector | Financials | Health |
52-Week High | $361.17 | $107.71 |
52-Week Low | $265.99 | $79.58 |
Enterprise Value | $155.34B | $24.66B |
Dividend Yield | 1.18% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $354.74, up 1.99% today, with a bullish technical outlook supported by moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $6.82 versus $6.60 expected, highlight robust profitability with a net income margin of 18.46% and ROE of 16.2%. The company maintains disciplined capital deployment, with a recent $1.02 dividend declared for H1 2026.
The stock offers a compelling value with a P/E of 12.55 and consensus price target of $361.67, though near-term risks include catastrophe losses and softer commercial pricing. Long-term growth is supported by premium expansion and investment income, but investors should monitor underwriting margins and market volatility.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
